Cargando…

Orogenital Human Papillomavirus Infection and Vaccines: A Survey of High- and Low-Risk Genotypes Not Included in Vaccines

Knowledge of human papillomavirus transmission from the genital tract to the oral mucosa remains unsatisfactory, with poor and often inconsistent literature results. The increase in HPV-associated oral malignancies prompts further analysis of the simultaneous detection of the virus in the two anatom...

Descripción completa

Detalles Bibliográficos
Autores principales: Buttà, Michela, Serra, Nicola, Panzarella, Vera, Fasciana, Teresa Maria Assunta, Campisi, Giuseppina, Capra, Giuseppina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10535452/
https://www.ncbi.nlm.nih.gov/pubmed/37766142
http://dx.doi.org/10.3390/vaccines11091466
_version_ 1785112632708038656
author Buttà, Michela
Serra, Nicola
Panzarella, Vera
Fasciana, Teresa Maria Assunta
Campisi, Giuseppina
Capra, Giuseppina
author_facet Buttà, Michela
Serra, Nicola
Panzarella, Vera
Fasciana, Teresa Maria Assunta
Campisi, Giuseppina
Capra, Giuseppina
author_sort Buttà, Michela
collection PubMed
description Knowledge of human papillomavirus transmission from the genital tract to the oral mucosa remains unsatisfactory, with poor and often inconsistent literature results. The increase in HPV-associated oral malignancies prompts further analysis of the simultaneous detection of the virus in the two anatomical areas and on the identification of genotypes to be included in future vaccines. Therefore, in this retrospective study, we evaluated orogenital HPV concurrence, hrHPV, lrHPV and type-concordance in 337 samples, as well as the prevalence of the most common genotypes not included in HPV vaccines. Concurrence was found in 12.5% (31/248) of cases, hr-concordance in 61.3% (19/31) and lr-concordance in 12.9% (4/31). Finally, type-concordance was found in 32.3% (10/31) of concurrent infections. Regarding the identification of non-vaccine genotypes, the significantly prevalent genotypes in the anogenital area were HPV66 (12.6%, p < 0.0001), HPV53 (11.1%, p < 0.0001), HPV51 (8.7%, p < 0.0001), HPV42 (8.2%, p < 0.0001) and HPV68 (5.6%, p = 0.0034) in women and HPV66 (14.6%, p = 0.0058), HPV42 (12.2%, p = 0.0428), HPV51 (12.2%, p = 0.0428), HPV53 (12.2%, p = 0.0428), HPV70 (12.2%, p = 0.0428) and HPV73 (12.2%, p = 0.0428) in men. Considering the results of our study, we recommend including the high-risk genotypes HPV51, HPV68, HPV53 and HPV66 in future HPV vaccine formulations.
format Online
Article
Text
id pubmed-10535452
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-105354522023-09-29 Orogenital Human Papillomavirus Infection and Vaccines: A Survey of High- and Low-Risk Genotypes Not Included in Vaccines Buttà, Michela Serra, Nicola Panzarella, Vera Fasciana, Teresa Maria Assunta Campisi, Giuseppina Capra, Giuseppina Vaccines (Basel) Article Knowledge of human papillomavirus transmission from the genital tract to the oral mucosa remains unsatisfactory, with poor and often inconsistent literature results. The increase in HPV-associated oral malignancies prompts further analysis of the simultaneous detection of the virus in the two anatomical areas and on the identification of genotypes to be included in future vaccines. Therefore, in this retrospective study, we evaluated orogenital HPV concurrence, hrHPV, lrHPV and type-concordance in 337 samples, as well as the prevalence of the most common genotypes not included in HPV vaccines. Concurrence was found in 12.5% (31/248) of cases, hr-concordance in 61.3% (19/31) and lr-concordance in 12.9% (4/31). Finally, type-concordance was found in 32.3% (10/31) of concurrent infections. Regarding the identification of non-vaccine genotypes, the significantly prevalent genotypes in the anogenital area were HPV66 (12.6%, p < 0.0001), HPV53 (11.1%, p < 0.0001), HPV51 (8.7%, p < 0.0001), HPV42 (8.2%, p < 0.0001) and HPV68 (5.6%, p = 0.0034) in women and HPV66 (14.6%, p = 0.0058), HPV42 (12.2%, p = 0.0428), HPV51 (12.2%, p = 0.0428), HPV53 (12.2%, p = 0.0428), HPV70 (12.2%, p = 0.0428) and HPV73 (12.2%, p = 0.0428) in men. Considering the results of our study, we recommend including the high-risk genotypes HPV51, HPV68, HPV53 and HPV66 in future HPV vaccine formulations. MDPI 2023-09-07 /pmc/articles/PMC10535452/ /pubmed/37766142 http://dx.doi.org/10.3390/vaccines11091466 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Buttà, Michela
Serra, Nicola
Panzarella, Vera
Fasciana, Teresa Maria Assunta
Campisi, Giuseppina
Capra, Giuseppina
Orogenital Human Papillomavirus Infection and Vaccines: A Survey of High- and Low-Risk Genotypes Not Included in Vaccines
title Orogenital Human Papillomavirus Infection and Vaccines: A Survey of High- and Low-Risk Genotypes Not Included in Vaccines
title_full Orogenital Human Papillomavirus Infection and Vaccines: A Survey of High- and Low-Risk Genotypes Not Included in Vaccines
title_fullStr Orogenital Human Papillomavirus Infection and Vaccines: A Survey of High- and Low-Risk Genotypes Not Included in Vaccines
title_full_unstemmed Orogenital Human Papillomavirus Infection and Vaccines: A Survey of High- and Low-Risk Genotypes Not Included in Vaccines
title_short Orogenital Human Papillomavirus Infection and Vaccines: A Survey of High- and Low-Risk Genotypes Not Included in Vaccines
title_sort orogenital human papillomavirus infection and vaccines: a survey of high- and low-risk genotypes not included in vaccines
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10535452/
https://www.ncbi.nlm.nih.gov/pubmed/37766142
http://dx.doi.org/10.3390/vaccines11091466
work_keys_str_mv AT buttamichela orogenitalhumanpapillomavirusinfectionandvaccinesasurveyofhighandlowriskgenotypesnotincludedinvaccines
AT serranicola orogenitalhumanpapillomavirusinfectionandvaccinesasurveyofhighandlowriskgenotypesnotincludedinvaccines
AT panzarellavera orogenitalhumanpapillomavirusinfectionandvaccinesasurveyofhighandlowriskgenotypesnotincludedinvaccines
AT fascianateresamariaassunta orogenitalhumanpapillomavirusinfectionandvaccinesasurveyofhighandlowriskgenotypesnotincludedinvaccines
AT campisigiuseppina orogenitalhumanpapillomavirusinfectionandvaccinesasurveyofhighandlowriskgenotypesnotincludedinvaccines
AT capragiuseppina orogenitalhumanpapillomavirusinfectionandvaccinesasurveyofhighandlowriskgenotypesnotincludedinvaccines